The occurrence of pathologically stable mRNAs of protooncogenes, growth factors and cyclins has been proposed to contribute to experimental and human oncogenesis. In normal resting cells, mRNAs containing an AU-rich element (ARE) in their 3 0 untranslated region are subjected to rapid degradation. Tristetraprolin (TTP) is an RNA-binding zinc-finger protein that promotes decay of ARE-containing mRNAs. Here we report that TTP acts as a potent tumor suppressor in a v-H-ras-dependent mast cell tumor model, where tumors express abnormally stable interleukin-3 (IL-3) mRNA as part of an oncogenic autocrine loop. Premalignant v-H-ras cells were transfected with TTP and injected into syngeneic mice. TTP expression delayed tumor progression by 4 weeks, and late appearing tumors escaped suppression by loss of TTP. When transfected into a fully established tumor line, TTP reduced cloning efficiency in vitro and growth of the inoculated cells in vivo. Transgenic TTP interfered with the autocrine loop by enhancing the degradation of IL-3 mRNA with concomitant reduction of IL-3 secretion. Our data establish the ARE as an antioncogenic target in a model situation, underline the importance of mRNA stabilization in oncogenesis and show for the first time that tumor suppression can be achieved by interfering with mRNA turnover.
Introduction
The AU-rich element (ARE) is the major regulatory element that targets cytokine and proto-oncogene mRNAs for rapid degradation and ensures that these transcripts are short-lived in resting cells. AREs are localized in the 3 0 untranslated region (UTR) of the mRNA, and three types could be distinguished based on structural analysis and deadenylation kinetics (Chen and Shyu, 1995) . In vitro mRNA decay studies suggest a model in which the ARE in a first step promotes deadenylation and decapping of the mRNA (Ford et al., 1999; Gao et al., 2001) . Subsequent degradation of the mRNA in the 3 0 to 5 0 direction is mediated by the exosome, either through its interaction with AREbinding proteins such as tristetraprolin (TTP) and KSRP (Chen et al., 2001) , or by direct binding of the exosomal protein PM-Scl75 to the ARE (Mukherjee et al., 2002) . The physiological role of AREs is to mediate efficient regulation at the post-transcriptional level. Extracellular stimulation transiently antagonizes ARE-dependent mRNA decay via activation of c-jun Nterminal protein kinase (JNK), p38 MAP-kinase and phosphatidylinositol-3-kinase pathways Ming et al., 1998 Ming et al., , 2001 Winzen et al., 1999) , and thereby amplifies cytokine induction. Once the activation signal has vanished, the ARE ensures rapid return to the low levels of basal expression. The mechanism of mRNA stabilization is likely to involve ARE-binding proteins as adaptors between the signalling cascade and the decay machinery (Carballo et al., 2001; Mahtani et al., 2001) . ARE-binding proteins with assigned functions in vivo include TTP, butyrate response factor-1 (BRF1) and AUF1, all of which promote degradation, as well as HuR that exerts an mRNA stabilizing effect (Carballo et al., 1998; Fan and Steitz, 1998; Peng et al., 1998; Loflin et al., 1999; Lai et al., 2000; Stoecklin et al., 2002) .
In view of the fact that during cell activation phosphorylation events stabilize ARE-mRNAs, it is perhaps not surprising that abnormally stable mRNAs occur in tumor cells (Eick et al., 1985; Aghib et al., 1990; Ross et al., 1991; Keyomarsi and Pardee, 1993; Conne et al., 2000; Dixon et al., 2001) , which generally exhibit constitutively active signalling pathways. In addition, mutation of an ARE in cis, or loss of a trans-acting decay effector may lead to oncogenic mRNA stabilization, and evidence for both mechanisms has been provided in experimental hemopoietic tumor systems by us and others (Schuler and Cole, 1988; Algate and McCubrey, 1993; Nair et al., 1994; Hirsch et al., 1995) . In the tumor model used for this study, mRNA stabilization occurs in the IL-3-dependent mast cell line PB-3c upon transformation with the v-H-ras oncogene. While normal resting PB-3c mast cells do not express IL-3, the cytokine is induced by treatment with calcium ionophore, which involves JNK-mediated stabilization of IL-3 mRNA (Wodnar-Filipowicz et al., 1989; Ming et al., 1998 ). Introduction of v-H-ras into PB-3c cells is not sufficient for direct malignant transformation. Following in vivo inoculation, however, IL-3-secreting autocrine tumors emerge after a long latency . Interestingly, many thus generated tumors lines are characterized by abnormally stable IL-3 transcripts (Nair et al., 1994; Hirsch et al., 1995) . The presumed oncogenic mutation acts in trans, since ARE-containing reporter transcripts were also stable in the tumor, but labile in the precursor cells. Somatic cell fusion studies revealed that transcript stability resulted from a recessive loss-of-function mutation, as rapid decay resumed upon fusion with parental PB-3c cells (Hirsch et al., 1996) . Furthermore, IL-3 mRNA in the tumor lines was destabilized by treatment with the calcineurin inhibitors cyclosporin A and FK506, as well as by the TOR-inhibitor rapamycin, indicating that oncogenic mRNA stabilization was maintained by parallel phosphorylation and dephosphorylation activities (Banholzer et al., 1997; Nair et al., 1994) . Growth of tumor cells could be inhibited in vitro by treatment with cyclosporin A or by blocking the autocrine loop extracellularly with anti-IL-3 antibodies (Nair et al., , 1994 .
The identification of TTP as a regulator of AREmRNA degradation has suggested a novel strategy to interfere with deregulated mRNA turnover in tumors. TTP is a zinc-finger protein of the unusual CCCH class initially cloned as an early response gene (Lai et al., 1990) . Knockout mice revealed that TTP acts as a negative regulator of TNFa expression by binding to the ARE of TNFa mRNA and accelerating its degradation (Carballo et al., 1998; Lai et al., 1999) . As TTP can also target the ARE of IL-3 Lai et al., 2002) , we speculated that TTP might act as a tumor suppressor in tumor cells characterized by abnormal stability of IL-3 mRNA. In this report, we verify this hypothesis by demonstrating that transfection of TTP not only suppresses tumor progression of premalignant v-H-ras cells to the malignant phenotype, but also inhibits both in vitro and in vivo growth of a fully established autocrine tumor line.
Results

Influence of TTP on v-H-ras-dependent tumor progression
The PB-3c subclone 15, upon transfection of v-H-ras, progresses in vivo to full malignancy with the induction of autocrine IL-3 secretion . To test whether expression of TTP has an influence on tumor progression, 15ras cells were transfected with a plasmid carrying both a myc-tagged TTP cDNA (TTP wt ) and a hygromycin-resistance marker. After stable selection and subcloning, TTP-positive (TTP + ) and TTP-negative (TTP À ) clones were identified by Western blot analysis (Figure 1b) . By Northern blot analysis, the expression level of exogenous TTP (mRNA) was found to be 2.5-5-fold higher compared to the endogenous TTP level (data clones formed tumors after 6 weeks, while tumors from the TTP + clones became apparent only after a median interval of 10 weeks. In all, 12 of these late tumors were explanted for tissue culture and analysed for TTP expression (Figure 1d ). In comparison to the injected TTP + clones (lanes 2, 7 and 12), a drastic reduction of TTP expression was observed in all 12 tumors both at the protein level (lanes 3-6, 8-11 and 13-16, upper panel) and at the mRNA level (lower panel). Using three of these tumor lines, we further tested whether addition of hygromycin to the medium would allow to reselect TTP-positive cells ( Figure 1e ). This was the case with two tumor lines (lanes 4 and 12), while in one tumor, TTP expression was permanently lost (lane 8). We concluded that TTP causes partial tumor suppression in this progression model, and that tumor progression selects against TTP expression.
V-abl-induced tumor formation is not affected by TTP
In order to determine whether the suppressive effect of TTP was specific for autocrine tumors, we made use of the v-abl oncogene that transforms PB-3c cells in a nonautocrine manner. In contrast to v-H-ras, v-abl renders the cells immediately independent of IL-3, and tumor formation occurs very early without activation of IL-3 (Nair et al., 1992) . 15abl cells were transfected with TTP wt and, as a negative control, with TTP C139R which contain a mutation in the second zinc-finger domain and is unable to bind RNA (see Figure 4d ). We chose two subclones of each transfection, confirmed the expression of v-abl ( Figure 2a ) and TTP (Figure 2b ), and injected 10 6 cells into five animals per clone. The v-abl-induced tumors already occurred after 2 weeks with no significant difference between the TTP wt and TTP C139R clones ( Figure 2c ). In a control group injected with untransfected 15abl cells, all tumors also occurred after 2 weeks (data not shown). Four tumors derived from 15abl-TTP wt cells were examined for TTP expression, and the levels were found to be unchanged compared to the parental cells ( Figure 2d ). We concluded that v-ablinduced mast cell transformation is not affected by TTP.
TTP reduces IL-3 expression in an established tumor line
We now wished to see whether TTP would also affect the behavior of an established tumor line derived from v-H-ras-expressing PB-3c cells. We chose the prototypic tumor line V2D1 characteristic for expressing abnormally stable IL-3 mRNA (Nair et al., 1994; Hirsch et al., 1995) , introduced TTP wt and TTP C139R by electroporation, and selected four subclones each ( Figure 3a , lanes 2-5 and 6-9). Northern blots performed after 4 weeks ( Figure 3b ) indicated that IL-3 mRNA levels were reduced in the TTP wt clones (lanes 2-5) compared to the TTP C139R clones (lanes 6-9). This was also reflected by a four to fivefold reduction of the IL-3 levels secreted by three out of four V2D1-TTP wt clones (Figure 3c ), as measured 7 weeks after subcloning. When these experiments were repeated at later times after several passages, a significant difference in IL-3 secretion was not observed anymore (data not shown). Western blots at 9 weeks revealed that TTP wt expression had actually been lost during passaging of the cell cultures ( Figure 3d , lanes 2-9), whereas the inactive TTP C139R protein remained stably expressed (lanes 10-17). The same observation was made in two repeat transfections (data not shown). Taken together, transfected TTP wt appeared to inhibit IL-3 expression, but was itself subjected to negative selection during in vitro passaging.
TTP accelerates decay of IL-3 mRNA by binding to the ARE
We next investigated in more detail the mechanism by which TTP reduced IL-3 expression. For this purpose, we made use of V2D1-TTP wt -6, a clone that we found to Figure 4a ). Northern blot analysis confirmed that IL-3 mRNA levels were much lower in V2D1-TTP wt -6 compared to V2D1 cells ( Figure 4b ). Actinomycin D chase experiments were performed to measure mRNA stability (Figure 4c ), and IL-3 mRNA decay was indeed found to be accelerated in V2D1-TTP wt -6 (half-life of 1.8 h70.33, n ¼ 3) compared to parental V2D1 (4.8 h70.03) or control V2D1-TTP C139R #10 cells (>6 h). The change in IL-3 mRNA stability in TTP wt -transfected V2D1 cells might be a direct or indirect effect of TTP. To address this question, we tested whether TTP could interact in vitro with the target RNA by gel mobility shift assays. A recombinant GST-TTP fusion protein was incubated with a radiolabelled RNA containing the ARE of IL-3 and resolved through nondenaturing gel electrophoresis ( Figure 4d ). Efficient complex formation was achieved with 50 ng or more of GST-TTP wt protein (middle panel), while GST alone did not bind to the RNA (left panel). Disruption of the second zinc-finger in murine TTP by the mutation C139R abolished binding to the ARE-containing RNA (right panel), which is in accordance to a corresponding mutation in human TTP (Lai et al., 1999) . Taken together, these data strongly suggested that repression of IL-3 occurred through direct interaction of TTP with the mRNA.
TTP suppresses tumor growth
In order to examine the effect of TTP on cell proliferation, V2D1 and V2D1-TTP wt -6 cells were cultured in the presence or absence of IL-3. Expression of TTP did not affect the proliferation rate of the mass culture under either condition (Figure 5a ). When tested for IL-3 secretion (Figure 5b ), V2D1 cells accumulated high levels of IL-3 in the supernatant after 3 days of culture, whereas IL-3 did not raise above basal levels in the V2D1-TTP-6 culture even after 5 days. Besides confirming the result obtained in Figure 3c , this indicated that the latter cells use up virtually all the IL-3 they produce. Therefore, we examined whether the cloning efficiency would be affected by TTP expression. (upper panel) . Cell cultures were routinely passaged in IL-3-containing medium, and lysates were prepared 4 and 9 weeks after subcloning. Membranes were stained for total protein using naphthol blue to control for equal loading (lower panel) Figure 4 Effect of TTP expression on IL-3 mRNA stability, (a) TTP wt expression in subclone V2D1-TTP wt -6 was monitored over 23 weeks of in vitro passaging (lanes 2-4) by Western blot analysis using an anti-myc antibody. Untransfected V2D1 is shown as negative control (lane 1). (b) Steady-state level expression of IL-3 mRNA was compared between V2D1 and V2D1-TTP wt -6 cells by Northern blot analysis, (c) IL-3 mRNA stability was determined by treating cells with actinomycin D for 0, 1, 2 and 4 h, followed by Northern blot analysis. IL-3 mRNA signal intensities were quantified by phosphoimager, normalized to the actin signal, and half-lives (mean values7s.e.) were calculated by linear regression: 4.8 h70.03 (V2D1), 1.8 h70.33 (V2D1-TTP wt -6) and >6 h (V2D1-TTP C139R #10). (d) Gel mobility shift assays were performed with increasing amounts of recombinant GST alone (left), GST-TTP wt (middle) and GST-TTP C139R (right panel) using a radiolabelled RNA containing the ARE of IL-3
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In the presence of IL-3 added to the medium, the cloning efficiency was between 80 and 85% irrespective of TTP expression (Figure 5c ). In the absence of IL-3, however, the cloning efficiency of V2D1 was only 9.0%, and TTP reduced the cloning efficiency to 2.3%.
To test whether there was also a difference in the growth of the tumor in vivo, groups of five mice were inoculated with V2D1 and V2D1-TTP wt -6 cells at two different doses (10 4 and 10 5 per animal). All V2D1 tumors became visible after 6 weeks. Most of the V2D1-TTP wt -6 tumors were apparent at the same time, except that 2/5 mice from group B (10 4 cells injected) developed visible tumors only after 17 weeks. A striking difference was manifest in the size of the tumors (Figure 5d ). Compared to the V2D1 tumors (groups A and C), the mean tumor weight of the V2D1-TTP wt -6 tumors (groups B and D) was reduced by 89 and 76% in the groups injected with 10 4 and 10 5 cells, respectively (Table 1 ). The reduction in tumor size was significant for both doses despite the small number of animals used. Together, these data argue that TTP, by destabilizing IL-3 mRNA and thereby interfering with the autocrine loop, also exerts a tumor suppressive effect on the established tumor in vivo.
Discussion
In the PB-3c tumor model, IL-3-dependent mast cells progress after transformation with v-H-ras to autocrine tumor cells with abnormally stable IL-3 transcripts. Somatic cell fusion between tumor and precursor cells re-establishes rapid IL-3 mRNA decay and IL-3-dependency with concomitant loss of oncogenicity. This had previously led us to formulate the hypothesis that a regulator of mRNA turnover, driving ARE-mRNA decay, may be a tumor suppressor Hirsch et al., 1996) . With the discovery of TTP being an ARE-binding protein and regulator of TNFa mRNA decay (Carballo et al., 1998) , it was tempting to speculate that this zinc-finger protein might exert tumor suppressor activity. We have tested this now in two settings: first, by transfection of TTP into premalignant 15ras cells (tumor progression), and second, by expression in fully autocrine V2D1 cells (tumor growth).
Upon introduction into 15ras cells, TTP was found to exert a negative effect on tumor progression (Figure 1) . Although inhibition was not complete, TTP expression caused a significant delay of 4 weeks for tumors to appear. Notably, analysis of these late tumors revealed that they had actually lost TTP expression, which strengthens the argument that TTP suppresses tumor growth. Loss of TTP expression was apparently not because of promoter methylation, as TTP could not be reinduced by treatment with 5-azacytidine (data not shown), whereas addition of hygromycin allowed to reselect TTP-positive cells from the explanted tumor. This points to a mechanism by which some cells upon injection into the animal lose transgenic TTP, overgrow As a control, the effect of TTP was tested in clone 15 cells transformed with v-abl (Figure 2 ). This oncogene, in contrast to v-H-ras, leads to immediate abrogation of IL-3-dependency, does not induce an autocrine loop and directly transforms mast cells with no need for an additional progression step (Nair et al., 1992) . In this case, TTP was unable to suppress tumor formation, which is consistent with the interpretation that TTP is effective in tumors that require expression of an AREcontrolled growth regulator such as IL-3. Accordingly, explants from the v-abl tumors showed no loss of TTP expression, and no selection for TTP-negative cells occurred.
The suppressive effect of TTP was confirmed by transfection into malignant V2D1 tumor cells with an already established autocrine loop. A reduction of IL-3 mRNA and protein levels by transgenic TTP expression could be observed when cells were examined 4-7 weeks after subcloning (Figure 3) . However, expression of wt TTP wt , but not of the inactive mutant TTP C139R , was lost by week 9. Mutant TTP remaining stably expressed is a strong argument that there is a negative selection pressure specifically directed against transgenic expression of active TTP, which occurs not only in vivo (Figure 1d ), but also in vitro (Figure 3d) .
A particular clone, V2D1-TTP wt -6, maintained TTP expression over 23 weeks, which allowed to show that TTP accelerates IL-3 mRNA degradation (Figure 4) . Presumably, TTP exerts its function by targeting AREmRNA to the exosome, as it has been described in an in vitro decay system (Chen et al., 2001 ). When we compared growth of the V2D1 and V2D1-TTP wt -6 cell cultures, the proliferation rate was not affected by TTP ( Figure 5 ). The cloning efficiency, however, was reduced when tested in the absence of exogenously added IL-3. This apparent contradiction is reminiscent of our previous observation that treatment of V2D1 cells with IL-3 antibodies inhibits the cloning efficiency in methylcellulose without affecting growth at higher density in suspension culture . This indicates that the cells are particularly vulnerable to a weakening of the autocrine loop at a very low density when single cells depend entirely on their own IL-3 production for survival. In this situation, the IL-3 secreted by the cloned cell is strongly diluted by diffusion into the medium. At higher density, paracrine secretion presumably enables the cells to proliferate at a normal rate even if low levels of IL-3 are being secreted. Monitoring IL-3 secretion of the higher density culture (Figure 5b ) confirmed that V2D1-TTP-6 cells produce just enough IL-3 to maintain their normal growth rate. In vivo, the very early stage of tumor formation may correspond to the cloning situation as few transformed cells need to survive in a growth factorpoor environment. Consistent with this hypothesis is the suppressive effect that we observed for transgenic TTP on tumor growth. Transplantation of V2D1-TTP wt -6 cells into recipient mice caused a dramatic reduction of tumor size compared to parental V2D1 cells (Table 1 and Figure 5d) .
Our results validate the hypothesis that an RNAbinding protein affecting mRNA turnover can act as a tumor suppressor. As with classical loss-of-function tumor suppressor genes (Hanahan and Weinberg, 2000; Knudson, 2000) , TTP or a closely related gene may be mutated in the tumor cells and transfection restores the missing function. We have sequenced the entire coding region of TTP and BRF1, a structurally related AREbinding zinc-finger protein that also regulates cytokine mRNA turnover (Lai et al., 2000; Stoecklin et al., 2002) . In V2D1 tumor cells, no mutation was detected in either gene, and transcripts were of expected size and expressed at the same levels as in parental PB-3c cells (data not shown). While we do not know the mutation(s) responsible for the V2D1 phenotype, it appears that forced expression of TTP can correct the dysbalance between stabilizing and destabilizing activities that control IL-3 mRNA stability in the tumor cell.
Besides targeting the AREs of IL-3, TNFa and GM-CSF, which are composed of a cluster of six or seven AUUUA pentamers, TTP can also mediate decay through the structurally distinct AREs of IL-2 and IL-6 which contain only four, more dispersed AUUUA motifs . A recent study using RNA SELEX has identified the UUAUUUAUU motif as the optimal sequence for binding of TTP in vitro, and showed that the AREs of c-fos, interferon-b and -g can also bind (Worthington et al., 2002) . Since a series of regulators relevant for oncogenic growth including cyclins, growth factors and proto-oncogenes contain AREs with an UUAUUUAUU motif (Chen and Shyu, 1995) , it is conceivable that TTP in fact has a broader spectrum of target mRNAs in the tumor cells. Such targets may also include antiapoptotic genes, as continuous expression of TTP was observed to induce apoptosis in various cell lines (Johnson et al., 2000) . Although we formally cannot exclude the possibility of Tumor suppressive effect of TTP G Stoecklin et al other targets being important for tumor suppression, IL-3 mRNA is likely to be the main target for TTP in the PB-3c tumor model for the following reasons: First, the ras-induced tumors are particulatly dependent on autocrine IL-3 secretion as demonstrated by the inhibitory effect of anti-IL-3 antibodies on the cloning efficinecy in methylcellulose . Second, IL-3 secretion was lower in the TTP-transfected tumor lines compared to controls (Figures 3c and 5b) , and third, the cloning efficiency of V2D1 was reduced by overexpression of TTP in the absence, but not in the presence of exogenously added IL-3 (Figure 5c ).
The ARE is clearly an antioncogenic target in the v-H-ras-dependent PB-3c mast cell tumor model reported here, where oncogenic growth is due to a stabilized ARE-transcript. A number of studies indicate that this mechanism may also be relevant to human carcinogenesis, and that TTP might play a role in spontaneous tumors. In an open search of genes relevant for oncogenic growth using retroviral insertion mutagenesis, TTP (also termed Zfp36) was identified as a candidtate gene in more than one tumor (Li et al., 1999) . Mice transgenic for AUF1, another ARE-binding protein, developed sarcomas (Gouble et al., 2002) . Increased stability of cyclin mRNA was observed in human breast cancer cells (Keyomarsi and Pardee, 1993) , and more recently cyclooxygenase-2 and VEGF mRNA, which both contain canonical AREs, were reported to be abnormally stable in colon carcinoma cells (Dixon et al., 2001) . The latter study pointed towards a role of the ARE-binding and RNA-stabilizing protein HuR. Similarly, HuR was shown to be highly expressed in strongly proliferating brain tumors and to bind with high affinity to the 3 0 UTRs of serveral oncogenic regulators including VEGF and cyclooxygenase-2 ). In conclusion, we propose that for tumors with defective AREdependent mRNA degradation, the development of pharmacological or genetic means to reinstall rapid mRNA decay may provide an effective antioncogenic strategy.
Materials and methods
Plasmid construction
First, plasmid pcDNA3.1MX was generated by cloning the 628 bp long MunI-SmaI fragment of vector pLXSN (Clontech) into the MunI and NheI sites of pcDNA3.1/Hygro (Invitrogen) to replace the CMV promoter by a Moloney Murine Leukemia Virus 5 0 LTR promoter. For plasmid hphMX-TTP wt , the myc/His-tagged murine TTP cDNA was excised as a HindIII-PmeI fragment from mTTP.tag (Stoecklin et al., 2000) and inserted into the HindIII and ApaI sites of pcDNA3.1MX. For plasmid hphMX-TTP C136R , the cysteine residue at position 139 (TGC) was changed to arginine (CGC) using QuickChange TM site-directed mutagenesis (Stratagene).
Cell culture and transfection
Origin and culture conditions of the PB-3c-derived mast cell lines 15ras (previously termed 15V4), 15abl and the tumor line V2D1 have been described earlier . For stable transfection, 10 mg of hphMX-TTP wt or hphMX-TTP C136R plasmid were linearized at a unique MunI site and electroporated into 5 Â 10 6 cells using a pulser at 250 V and 1950 mF (Easyjec T plus, Equibio). Selection was initiated 48 h later with hygromycin B (1 mg/ml; Calbiochem), and subcloning of the stably transfected cells was performed as described below.
Mice and tumorigenicity experiments
Female DBA/2 mice (8-12 weeks old) were used for subcutaneous injection of syngeneic PB-3c cells into the gluteal region. Mice were scored weekly for appearance of tumors, and killed using CO 2 for explantation of tumor cells. Housing and protocols were in accordance with federal regulation on animal experimentation.
RT-PCR
To detect expression of retrovirally transduced v-H-ras and vabl, RT-PCR was performed using standard protocols and the following primers: M1398 (5 0 -CTGGCTGCATGAGCTGCA-AG-3 0 ) and M1402 (5 0 -GCGGACTGGCTTTCTACGTG-3 0 ) for ras-neo, M2209 (5 0 -CACTGGAAAGATGTCGAGCG-3 0 ) and M2212 (5 0 -GTGTTGATCCTGTAGTGGTAC-3 0 ) for gagabl and M1171 (5 0 -ACATCAAAGAGAAGCTGTGC-3 0 ) and M1170 (5 0 -ACTGTGTTGGCATAGAGGTC-3 0 ) for actin.
Western blot
Cell lysates were prepared in a buffer containing 10 mm HEPES (pH 7.6), 40 mm KCl, 3 mm MgCl 2 , 0.2% NP-40, 5% glycerol, 1 mm DTT and complete protease inhibitors (Roche). Total protein concentration was measured by Bradford assay, and 50 mg were loaded in each lane. Monoclonal 9E10 antibody was used for detection of myc-tagged TTP. Total protein was visualized with 1% naphthol blue black solution (Fluka) in H 2 O.
Northern blot
RNA isolation and Northern blot analysis were performed as described previously (Stoecklin et al., 2000) . Equal amounts of RNA were loaded in each lane (50 or 100 mg). Radiolabelled RNA-probes were generated from SP6 vectors containing a 368 bp HindIII-XbaI IL-3 cDNA fragment, a 392 bp 3 0 terminal IL-3 cDNA fragment and a 567 bp PstI chicken bactin fragment. TTP was detected with a random-primed DNA-probe generated from full-length TTP cDNA.
Gel mobility shift assay 32 P-labelled RNA was synthesized in vitro using SP6 RNA polymerase (Promega) and plasmid SP6-IL3-3 0 UTR as the template, which contains a 380 nt long IL-3 cDNA fragment encompassing the entire 3 0 UTR. RNA (10 5 cpm) was incubated with 10-500 ng of purified GST-TTP fusion protein as described elsewhere (Stoecklin et al., 2002) and resolved by 4% nondenaturing polyacrylamide gel electrophoresis.
Mitogenicity assay
Cells were seeded at a concentration of 2 Â 10 5 /ml in IL-3-free medium, and supernatants were harvested after 72 h. Supernatants were assayed at a 1/2 dilution on IL-3-dependent 15ras cells (2 Â 10 4 /100 ml). After incubation for 24 h, 3 H-thymidine (85 Ci/mmol, Amersham) was added
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